TY - JOUR
T1 - Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw
T2 - Preliminary findings
AU - Kakehashi, H.
AU - Ando, T.
AU - Minamizato, T.
AU - Nakatani, Y.
AU - Kawasaki, T.
AU - Ikeda, H.
AU - Kuroshima, S.
AU - Kawakami, A.
AU - Asahina, I.
N1 - Funding Information:
This study was supported in part by a Grant-in-Aid from Scientific Research (C) (Research number 26463016).
Publisher Copyright:
© 2015 International Association of Oral and Maxillofacial Surgeons.
PY - 2015
Y1 - 2015
N2 - Teriparatide is a synthetic polypeptide hormone that contains the 1-34 amino acid fragment of the recombinant human parathyroid hormone that stimulates bone formation. Currently, it is approved only for the treatment of osteoporosis. The outcomes of daily teriparatide injections for the treatment of bisphosphonate-related osteonecrosis of the jaw in 10 patients are reported here. Two of the 10 cases dropped out due to adverse events. Of the remaining eight cases, seven exhibited clinical improvement of the jaw-related symptoms of osteonecrosis and progression of the sequestration, while one case did not show improvement of the symptoms. Administration of teriparatide in patients with osteonecrosis of the jaw promotes bone formation and subsequent sequestration over a short period of time. These results suggest that adjunctive teriparatide therapy is a viable and effective option for treating osteonecrosis of the jaw.
AB - Teriparatide is a synthetic polypeptide hormone that contains the 1-34 amino acid fragment of the recombinant human parathyroid hormone that stimulates bone formation. Currently, it is approved only for the treatment of osteoporosis. The outcomes of daily teriparatide injections for the treatment of bisphosphonate-related osteonecrosis of the jaw in 10 patients are reported here. Two of the 10 cases dropped out due to adverse events. Of the remaining eight cases, seven exhibited clinical improvement of the jaw-related symptoms of osteonecrosis and progression of the sequestration, while one case did not show improvement of the symptoms. Administration of teriparatide in patients with osteonecrosis of the jaw promotes bone formation and subsequent sequestration over a short period of time. These results suggest that adjunctive teriparatide therapy is a viable and effective option for treating osteonecrosis of the jaw.
UR - http://www.scopus.com/inward/record.url?scp=84960910687&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84960910687&partnerID=8YFLogxK
U2 - 10.1016/j.ijom.2015.07.018
DO - 10.1016/j.ijom.2015.07.018
M3 - Article
C2 - 26304604
AN - SCOPUS:84960910687
SN - 0901-5027
VL - 44
SP - 1558
EP - 1564
JO - International Journal of Oral and Maxillofacial Surgery
JF - International Journal of Oral and Maxillofacial Surgery
IS - 12
ER -